Related Experiment Video

Updated: Jul 18, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Cardiac resynchronization therapy for CHF. The rewards and risks of biventricular pacing

Sanjeev Wasson1, Donald J Voelker, Pitt Vesom

  • 1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. sanjeevwasson@hotmail.com

Postgraduate Medicine
|November 30, 2006
PubMed

Insights

Cardiac resynchronization therapy (CRT) offers a cost-effective, widely applicable treatment for moderate to severe heart failure. Its percutaneous delivery and ease of use are making it an increasingly recognized option for heart failure patients.

Area of Science:

  • Cardiology
  • Medical Devices

Background:

  • Advanced heart failure (HF) presents significant morbidity and mortality challenges despite current pharmacotherapies like beta-blockers and angiotensin-aldosterone inhibitors.
  • Limitations of existing treatments include the scarcity of donor organs for cardiac transplantation and the cumbersome, costly nature of approved heart-assist devices, restricting their use to specialized centers.
  • Most patients with congestive heart failure (CHF) are ineligible for cardiac transplantation, and current mechanical circulatory support options are not widely accessible.

Purpose of the Study:

  • To highlight the evolving role and benefits of Cardiac Resynchronization Therapy (CRT) as a therapeutic option for patients with moderate to severe heart failure.
  • To emphasize the advantages of CRT, including its percutaneous applicability, cost-effectiveness, and ease of use, in contrast to traditional treatments.

Main Methods:

  • This study reviews the current landscape of advanced heart failure treatments.
  • It focuses on the characteristics and benefits of Cardiac Resynchronization Therapy (CRT) delivery via a percutaneous method.
  • The analysis contrasts CRT with limitations of cardiac transplantation and existing heart-assist devices.

Main Results:

  • Cardiac Resynchronization Therapy (CRT) is emerging as a viable and beneficial treatment for moderate to severe heart failure.
  • CRT's percutaneous application and cost-effectiveness make it broadly accessible and attractive for symptomatic heart failure patients.
  • Physicians are increasingly recognizing the low threshold for initiating CRT due to its favorable profile.

Conclusions:

  • Cardiac Resynchronization Therapy (CRT) represents a significant advancement in managing symptomatic heart failure.
  • Its universal applicability, cost-effectiveness, and ease of percutaneous delivery position it as a preferred therapeutic strategy.
  • The growing awareness among physicians suggests a shift towards wider adoption of CRT for eligible heart failure patients.

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...